Understanding how antibiotics work against Shigella infections
Pharmacokinetic and pharmacodynamic relationships for antibacterial treatment of shigellosis
This study is looking at how well different antibacterial treatments work for Shigella infections, which can cause bad diarrhea, especially in kids, to find better options that can help fight off resistant strains of the bacteria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11061255 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of different antibacterial treatments for Shigella infections, which can cause severe diarrhea and dysentery, particularly in children. The study aims to identify how the characteristics of these treatments influence their success and the development of drug resistance. By establishing a framework for evaluating these relationships, the research seeks to optimize existing therapies and develop new ones. Patients may benefit from improved treatment options that are more effective against resistant strains of Shigella.
Who could benefit from this research
Good fit: Ideal candidates for this research include children under 11 years old who are experiencing Shigella infections, particularly in low-resource settings.
Not a fit: Patients with Shigella infections who are not in the targeted age group or those who do not reside in areas affected by drug-resistant strains may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Shigella infections, reducing morbidity and mortality, especially in vulnerable populations.
How similar studies have performed: Previous research has shown success in understanding drug exposure relationships for other gastrointestinal pathogens, indicating potential for similar advancements in treating Shigella.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Arnold, Samuel L — University of Washington
- Study coordinator: Arnold, Samuel L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.